Sunday, January 21, 2018 10:38:25 AM
Fully Diluted O/S 88M shares!
“We welcome Nemus into Emerald’s family of life science companies,”
https://www.dailymarijuanaobserver.com/single-post/2018/01/19/NMUS-Nemus-Receives-400000-Under-Bridge-Loan-and-Closes-Private-Placement
Emerald holds a majority of Nemus’ common shares on a deemed fully converted basis. Nemus’ current directors have resigned, except for Dr. Brian Murphy, who has been joined by Punit Dhillon and Jim Heppell as directors of the company. Mr. Dhillon and Mr. Heppell are also directors of Emerald.
“We greatly value the intellectual capital and discovery capacity of the University of Mississippi, with which Nemus has an exclusive agreement for novel cannabinoid technologies. We will work to support the business and developmental vision of our CEO, Dr. Murphy, across a spectrum of medical indications of unmet need. The Emerald Board believes that Nemus presents a significant value proposition for investors and we look forward to advancing its pipeline into clinical development.”
http://beta.latimes.com/nation/la-na-pot-monopoly-20140529-story.html
"What makes the cannabis here on the campus of the University of Mississippi unique is that it is grown, processed and sold by the federal government. The stockpile represents the only source of pot allowed for researchers who want to conduct Food and Drug Administration-approved tests on using marijuana for medical purposes."
We intend to soon issue a pipeline development update reflecting the significant business opportunities available for our products and addressing molecule prioritization, associated goals, and timelines. We are looking forward to working with our new colleagues at Emerald and taking our first steps into human studies.”
Nemus Pipeline
http://www.nemusbioscience.com/research-and-cannabinoids/default.aspx
Nemus plans to utilize the capital raised to satisfy outstanding financial obligations and explore potential strategic opportunities which could possibly include a recapitalization plan and the potential uplisting of its shares onto a major stock exchange.
Emerald holds a majority of Nemus’ common shares on a deemed fully converted basis. Nemus’ current directors have resigned, except for Dr. Brian Murphy, who has been joined by Punit Dhillon and Jim Heppell as directors of the company. Mr. Dhillon and Mr. Heppell are also directors of Emerald.
http://emeraldhealth.ca/board-management/jim-heppell/#
http://emeraldhealth.ca/board-management/punit-dhillon/
http://emeraldhealth.ca/board-management/avtar-dhillon/
Lift Cannabis Expo | Interview with Chris Wagner
Chris Wagner, CEO of Emerland Health Therapeutics, explains Emerald's work with scientists and researchers around the world plus the importance of standardization, dosing and delivery - and more!
Great interview with Executive Chairman of Emerald Health Therapeutics, Dr. Avtar Dhillon.
https://www.directcannabisnetwork.com/meet-emerald-health-therapeutics/?utm_content=bufferc6a01&utm_medium=social&utm_source=twitter.com&utm_campaign=buffer
Recent SKYE News
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 09/23/2024 09:25:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/13/2024 10:56:11 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 09/13/2024 09:18:32 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/04/2024 10:12:34 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 09/04/2024 09:25:07 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 08/09/2024 09:29:35 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2024 09:18:47 PM
- Beacon Biosignals Announces Strategic Collaboration with Skye Bioscience to Integrate Sleep Quality and Sleep Apnea Endpoints in CBEYOND™ Phase 2 Trial of Nimacimab for Obesity • GlobeNewswire Inc. • 07/24/2024 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/10/2024 01:27:39 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 05/20/2024 04:15:09 AM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 05/17/2024 08:27:44 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 05/10/2024 08:19:14 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 05/10/2024 08:17:16 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 08:02:13 PM
FEATURED Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • Sep 24, 2024 8:50 AM
FEATURED Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM